The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-01 and is reviewed periodically as new material appears.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Due to the effect pH has on absorption, amphetamine also interacts with gastric acid reducers such as proton pump inhibitors and H2 antihistamines, which increase gastrointestinal pH (i.e., make it less acidic).
== Gene expression == The CCND1 gene encodes the cyclin D1 protein. The human CCND1 gene is located on the long arm of chromosome 11 (band 11q13). It is 13,388 base pairs long, and translates into 295 amino acids. Cyclin D1 is expressed in all adult human tissues with the exception of cells derived from bone marrow stem cell lines (both lymphoid and myeloid).
However at this time, using spider silk to grow artificial skin in mass quantities is not practical because of the tedious process of harvesting spider silk. Australian researchers are currently searching for a new, innovative way to produce artificial skin. This would produce artificial skin more quickly and in a more efficient way. The skin produced would only be 1 millimeter thick and would only be used to rebuild the epidermis. They can also make the skin 1.5 millimetres thick, which would allow the dermis to repair itself if needed. This would require bone marrow from a donation or from the patient's body. The bone marrow would be used as a "seed", and would be placed in the grafts to mimic the dermis. This has been tested on animals and has been proven to work with animal skin. Professor Maitz said, "In Australia, someone with a full-thickness burn to up to 80 per cent of their body surface area has every prospect of surviving the injury... However their quality of life remains questionable as we're unable, at present, to replace the burned skin with normal skin...We're committed to ensuring the pain of survival is worth it, by developing a living skin equivalent."
Sources: en.wikipedia.org
The report found that AI has significant negative impacts on land, water, and climate, as it uses large amounts of electricity, requires mining of minerals, and generates large amounts of electronic waste. In 2025, data centres consumed more electricity than Saudi Arabia, and ChatGPT alone consumed an amount of water equivalent to the needs of 500,000 people in Sub-Saharan Africa. The negative impacts are not distributed equally across the planet but are concentrated in some places. Data centres are often built in places already suffering from water deficit. For example, AI deployment has already led to an increase in water scarcity in Mexico and Uruguay. It created problems with energy supply in Ireland, which forbade construction of new data centres near Dublin until 2028. Measures can involve tradeoffs, for example, transitioning from coal to bioenergy reduces carbon footprint but increases the impact on land and water. Energy efficiency might not reduce environmental impact, because as AI becomes more efficient, it also becomes cheaper and more widely used.
(2026) reconstruct the evolutionary history of members of the genus Arvicola in Western Europe during the late Middle and Late Pleistocene on the basis of the study of morphology of teeth from the Lazaret Cave and Moula-Guercy sites (France), Abauntz Cave, Cova Eirós (Spain) and Trou Al'Wesse (Belgium), interpreted as consistent with a complex biogeographic history including multiple dispersals into Western Europe and subsequent local extinctions and recolonizations. New fossil material of members of the genus Byzantinia, providing new information on the morphology of teeth of members of this genus and their evolution, is described from the Miocene strata of the Zahleh Formation (Lebanon) by López-Antoñanzas et al. (2026). A study on the phylogenetic relationships and evolutionary history of extant and extinct hamsters is published by Dirnberger et al. (2026). Bujalska et al. (2026) reconstruct the evolutionary history of European small hamsters on the basis of mitochondrial genomes from Late Pleistocene and Holocene remains from Central and Western Europe, the Balkans and Anatolia, identifying evidence of presence of the winter white dwarf hamster in Central Europe during the Late Pleistocene. Pacheco-Castro, Carranza-Castañeda & Wang (2026) report the discovery of fossil material of Sigmodon minor from the Pliocene strata of the San Miguel de Allende Basin, representing the first record of the species from central Mexico and its southernmost known record in North America.
There are many types of treatment for the perichondral hematoma that can lead to cauliflower ear, but the current body of research is unable to identify a single best treatment or protocol. There is definitive evidence that the drainage of this hematoma is better for the prevention of cauliflower deformity when compared to conservative treatment, but the use of bandages and/or splinting after drainage requires more research. Because an acute hematoma can lead to cauliflower ear, prompt evacuation of the blood can prevent permanent deformity. There are many described techniques for the drainage of blood in the acute stage to prevent hematoma, including aspiration and drainage, incision and drainage, use of continuous suction devices and placing a wick. After the blood has been drained, the prevention of re-accumulation becomes the most pressing issue. This has been achieved with many techniques including: direct pressure dressings, in and out mattress sutures, buttons placed on sutures, thermoplastic splints, sutured cotton balls, and absorbable mattress sutures. The use of simple drainage becomes less useful after six hours from the injury and when there is recurrent trauma. In these cases it has been suggested that open surgical treatment is more effective in returning the cosmetic appearance and prevention of recurrence. The outer ear is prone to infections, so antibiotics are usually prescribed. Pressure can be applied by bandaging which helps the skin and the cartilage to reconnect.
Sources: en.wikipedia.org
=== Black Consciousness and empowerment === Biko rejected the apartheid government's division of South Africa's population into "whites" and "non-whites", a distinction that was marked on signs and buildings throughout the country. Building on Fanon's work, Biko regarded "non-white" as a negative category, defining people in terms of an absence of whiteness. In response, Biko replaced "non-white" with the category "black", which he regarded as being neither derivative nor negative. He defined blackness as a "mental attitude" rather than a "matter of pigmentation", referring to "blacks" as "those who are by law or tradition politically, economically and socially discriminated against as a group in the South African society" and who identify "themselves as a unit in the struggle towards the realization of their aspirations". In this way, he and the Black Consciousness Movement used "black" in reference not only to Bantu-speaking Africans but also to Coloureds and Indians, who together made up almost 90% of South Africa's population in the 1970s. Biko was not a Marxist and believed that it was oppression based on race, rather than class, which would be the main political motivation for change in South Africa. He argued that those on the "white left" often promoted a class-based analysis as a "defence mechanism... primarily because they want to detach us from anything relating to race. In case it has a rebound effect on them because they are white".
== Use and effects == The 2C drugs are orally active at doses of 6 to 150 mg, depending on the drug, and have durations of 3 to 48 hours, also depending on the drug. Several have doses in the range of 10 to 60 mg and durations in the range of 4 to 12 hours. The 2C drugs produce psychedelic effects, such as perceptual enhancement, psychedelic visuals, and euphoria. Some, such as 2C-B, have also been reported to produce some entactogen-like effects, but findings in this area appear to be mixed.
=== Breastfeeding in humanitarian emergencies === During humanitarian crises, conflicts, forced displacement, and natural disasters, mothers and caregivers face additional difficulties in maintaining adequate breastfeeding practices. They may experience physical and mental exhaustion, lack safe and private spaces for on-demand breastfeeding, and have limited social support. In many of these situations, unsolicited donations of breast milk substitutes may be distributed through well-intentioned but poorly informed solidarity initiatives. Relying on these products often interrupts breast milk production and creates dependence on formula milk, whose use carries critical health risks in settings where clean water and hygiene materials are not fully accessible. Following a key meeting hosted by the International Baby Food Action Network (IBFAN) in 1995, the Infant Feeding in Emergencies (IFE) Core Group was established in 1999 to address policy guidance and capacity-building on infant and young child feeding in emergencies. Over the years, and in collaboration with many other humanitarian organisations, the IFE Core Group has issued key recommendations aimed at monitoring and controlling unsolicited donations of breast milk substitutes, protecting early initiation of breastfeeding, providing food or financial assistance to caregivers, safeguarding infants who depend exclusively on formula milk, establishing and maintaining community support spaces for infant and young child feeding, and fostering inter-sectoral coordination to promote a positive environment for breastfeeding.
==== Potential path: sludge to food ==== PFOA and PFOS were detected in "very high" (low parts per million) levels in agricultural fields for grazing beef cattle and crops around Decatur, Alabama. The approximately 5000 acres of land were fertilized with "treated municipal sewage sludge, or biosolids". PFOA was also detected in fodder grass grown in these soils and the blood of the cattle feeding on this grass. The water treatment plant received process wastewater from a nearby perfluorochemical manufacturing plant. 3M says they managed their own wastes, but Daikin America "discharged process wastewater to the municipal waste treatment plant". If traced to meat, it would be the first time perfluorochemicals were traced from sludge to food. However, the USDA reported—with a detection limits of 20 parts per billion—non-detectable levels for both PFOA and PFOS in cattle muscle tissue.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.